18.90
0.86 (4.77%)
0.86 (4.77%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
Big Cap Pro
Monthly Subscription
for only
|
Small Cap Pro
Monthly Subscription
for only
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
VAT not included
|
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aclaris Therapeutics Inc | ACRS | NASDAQ | Common Stock |
Price Change | Change Percent | Stock Price | Last Traded ![]() |
|
---|---|---|---|---|
0.86 | 4.77% | 18.90 | 19:59:54 |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
17.54 | 17.16 | 18.59 | 18.22 | 18.04 |
Bid Price | Ask Price | Spread | News | |
---|---|---|---|---|
18.51 | 18.92 | 0.41 | 1 | - |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
12,612 | 1,394,749 | $ 17.98 | $ 25,080,975 | 5,450,750 | 0.70 - 24.28 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:16 | formt | 100 | $ 18.90 | USD |
Aclaris Therapeutics Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 811.17M | 42.92M | 40.88M | $ 12.98M | $ - | -3.90 | -14.10 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | 0.00% | - | - |
Aclaris Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACRS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 6.11 | 24.28 | 5.82 | 18.66 | 34,475,848 | 12.79 | 209.33% |
1 Month | 7.74 | 24.28 | 5.65 | 18.13 | 7,585,344 | 11.16 | 144.19% |
3 Months | 3.74 | 24.28 | 3.04 | 15.97 | 2,966,625 | 15.16 | 405.35% |
6 Months | 2.28 | 24.28 | 1.82 | 13.71 | 1,591,908 | 16.62 | 728.95% |
1 Year | 1.67 | 24.28 | 0.70 | 10.59 | 1,079,218 | 17.23 | 1,031.74% |
3 Years | 24.47 | 25.89 | 0.70 | 7.87 | 802,492 | -5.57 | -22.76% |
5 Years | 22.85 | 33.25 | 0.70 | 10.37 | 563,164 | -3.95 | -17.29% |
Aclaris Therapeutics Description
Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which operates in United States. It focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology. The company holds a drug candidate, A-101 Topical Solution which is a proprietary high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis (SK) a common non-malignant skin tumor. Its pipeline of drug candidates includes A-101 as a Topical Solution for treatment of SK, common warts; A-102 as a gel dosage form for treatment of SK and warts and A-201 and A-301 as an oral and topical formulation for treatment of autoimmune dermatologic respectively. |